


CLAIMS

1. A compound of formula (1)



5

(1)

wherein

R¹ is aryl; and

R² is hydrogen or alkyl;

and pharmaceutically acceptable addition compounds thereof.

10

2. A compound according to claim 1 wherein R¹ is an aryl group selected from phenyl and naphthyl.

3. A compound according to claim 1 or 2 wherein R¹ has 1, 2 or 3 substituent groups.

15

4. A compound according to ~~any preceding claim~~ ^{(C6H4) or 1} wherein R¹ is substituted with one or more substituent groups selected from halo, trifluoromethyl and tertiary-butyl.

20

5. A compound according to claim 4 wherein said halo groups are selected from chloro and fluoro.

6. A compound according to claim 1, ~~2, 3, 4 or 5~~ wherein R¹ is a meta- or para-substituted phenyl group.

25

7. A compound according to claim 1 wherein R¹ is selected from 4-chlorophenyl, 4-fluorophenyl, 4-(trifluoromethyl)phenyl and 3-(trifluoromethyl)phenyl.

8. A compound according to claim 1, ~~2, 3, 4 or 5~~ wherein R¹ is selected from a 2,3-disubstituted phenyl group, a 2,4-disubstituted phenyl group, a 3,4-disubstituted phenyl group and a 3,5-disubstituted phenyl group.
9. A compound according to claim 8 wherein R¹ is substituted by two halo groups, the same or different, or by one halo group and one trifluoromethyl group.
10. A compound according to claim 9 wherein R¹ is dichloro-substituted, difluoro-substituted, chloro-fluoro-substituted or fluoro-trifluoromethyl-substituted.
11. A compound according to claim 1 wherein R¹ is selected from 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-fluoro-4-(trifluoromethyl)phenyl, 4-fluoro-3-(trifluoromethyl)phenyl and 3-chloro-5-fluorophenyl.
12. A compound according to ~~any one of claims 1 to 11~~ ^{Claim 1} wherein R² is alkyl.
13. A compound according to ~~any one of claims 1 to 12~~ ^{Claim 1} wherein R² is C₁₋₈ alkyl.
14. A compound according to ~~any one of claims 1 to 13~~ ^{Claim 1} wherein R² is alkenyl, alkynyl, hydroxyalkyl or alkoxyalkyl.
15. A compound according to ~~any one of claims 1 to 13~~ ^{Claim 1} wherein R² is unsubstituted saturated cyclic or acyclic hydrocarbyl.
16. A compound according to ~~any one of claims 1 to 13~~ ^{Claim 1} wherein R² is propyl, 2-propenyl, 2-propynyl or 2-hydroxypropyl.
17. A compound according to claim 1 wherein the compound is selected from 3-(4-Chlorophenyl)-N-(2-propynyl)azetidine-1-carboxamide, (S)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Fluorophenyl)-N-(2-propynyl)azetidine-1-carboxamide, (R)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Chlorophenyl)-N-(2-propenyl)azetidine-1-carboxamide, (R)-3-(4-Chlorophenyl)-N-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(4-Fluorophenyl)-N-(2-propenyl)azetidine-1-

carboxamide, 3-(4-(Trifluoromethyl)phenyl)-*N*-(2-propynyl)azetidine-1-carboxamide, (*R*)-3-(4-(Trifluoromethyl)phenyl)-*N*-(2-hydroxypropyl)azetidine-1-carboxamide, (*S*)-3-(4-(Trifluoromethyl)phenyl)-*N*-(2-hydroxypropyl)azetidine-1-carboxamide, 3-(3-(Trifluoromethyl)phenyl)-*N*-(2-propynyl)azetidine-1-carboxamide and 3-(4-(Trifluoromethyl)phenyl)-*N*-azetidine-1-carboxamide.

18. A compound according to ~~any one of claims 1 to 17~~ for use in therapy.
19. Use of a compound according to ~~any one of claims 1 to 17~~ in the manufacture of a medicament for the treatment (including prophylaxis) of CNS disorders.
20. Use according to claim 19 wherein said medicament is for the treatment (including prophylaxis) of anxiety, epilepsy, insomnia, including travel insomnia and insomnia associated with terminal illness, alcohol withdrawal syndrome, chronic and acute pain, neurodegenerative diseases, symptoms relating to withdrawal from substance abuse or spasticity.
21. Use according to claim 19 wherein said medicament is for the treatment (including prophylaxis) of anxiety or epilepsy.
22. Use of a compound according to ~~any one of claims 1 to 17~~ in the manufacture of a medicament for muscle relaxation prior to surgery or surgical manipulation or as pre-medication prior to surgery.
23. A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 17~~ in combination with a pharmaceutically acceptable carrier or excipient.
24. A method of treatment (including prophylaxis) of CNS disorders comprising administering to a patient in need of such treatment an effective dose of a compound according to ~~any one of claims 1 to 17~~.
25. A method according to claim 24 wherein said method is for the treatment of anxiety, epilepsy, insomnia, including travel insomnia and insomnia associated with terminal illness,



-41-

alcohol withdrawal syndrome, chronic and acute pain, neurodegenerative diseases, symptoms relating to withdrawal from substance abuse or spasticity.

26. A method according to claim 24 wherein said method is for the treatment of anxiety
5 or epilepsy.

27. A method of muscle relaxation prior to surgery or surgical manipulation or a method
of pre-medication prior to surgery, comprising administering to a patient in need thereof an
effective dose of a compound according to ^{any one of claims 1 to 17} ~~any one of claims 1 to 17~~.

BY 


C7 

0950031.01.01